Navigation Links
Astellas Highlights Progress to Advance Care of Patients with Genitourinary Cancers at ASCO-GU Annual Meeting
Date:2/13/2013

l of 1,199 patients with mCRPC who had previously received docetaxel were randomized 2:1 to receive either XTANDI orally at a dose of 160 mg once daily (N = 800) or placebo (N = 399). Patients with a history of seizure, taking medications known to decrease the seizure threshold, or with other risk factors for seizure were excluded from the clinical trial. The primary endpoint of the trial was OS.

XTANDI-treated patients had a statistically-significant improvement in median OS compared to the placebo group: 18.4 months in the XTANDI group versus 13.6 months in the placebo group (P < 0.0001). XTANDI provided a 37% reduction in risk of death compared to placebo (hazard ratio = 0.631). Seizure occurred in 0.9% of patients on XTANDI and 0% of the placebo-treated patients. The most common adverse reactions (≥ 5%) are asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral edema, musculoskeletal pain, headache, upper respiratory infection, muscular weakness, dizziness, insomnia, lower respiratory infection, spinal cord compression and cauda equina syndrome, hematuria, paresthesia, anxiety, and hypertension. Grade 3 and higher adverse reactions were reported among 47% of XTANDI-treated patients and 53% of placebo-treated patients.

The recommended dose of XTANDI is 160 mg (four 40 mg capsules) administered orally once daily. XTANDI can be taken with or without food and does not require concomitant steroid (e.g., prednisone) use. In the phase 3 clinical trial, 48% of XTANDI patients and 46% of patients in the placebo arm were treated with glucocorticoids.

XTANDI Mechanism of Action

XTANDI (enzalutamide) is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. XTANDI has been shown to competitively inhibit androgen binding to androgen receptors, inhibit androgen receptor nuclear translocation and interaction with DNA. A major metabolite, N-desmethyl enzalutamide, exhibited
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
2. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
3. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
4. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
5. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
6. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
7. CTIA-The Wireless Association Highlights Connected Health Benefits and Potential
8. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
9. Philips Highlights Future Innovations at RSNA 2012 Transformation Lab
10. Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
11. CLAAD Highlights 5 Technologies To Reduce Prescription Drug Abuse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 2014   DaVita HealthCare Partners Inc.  (NYSE: ... largest and most innovative health care communities, today ... DaVita Clinical Research  (DCR) and  HealthCare Partners Clinical Research ... extensive clinical research and data analytics services, specifically ... end-stage renal disease (ESRD), as well as primary ...
(Date:12/13/2014)... 11, 2014 Research and Markets ... the "Drug Injection Devices to 2020" ... http://photos.prnewswire.com/prnh/20130307/600769 As new drugs ... list of health conditions, drug developers have increasingly ... administration process and increase the efficiency and reliability ...
(Date:12/13/2014)... Mindray Medical International Limited ("Mindray", NYSE: ... of medical devices worldwide, today announced shareholder resolutions adopted ... Hong Kong on December 10, ... to re-elect incumbent directors Li Xiting and Kern Lim, ... not re-elect Peter Wan as a director. ...
Breaking Medicine Technology:DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4Mindray Announced Shareholder Resolutions Post 2014 Annual General Meeting 2
... Sept. 1, 2011 Lifetime Products, Inc. -- a ... goods equipment, outdoor storage sheds, and lawn and garden ... product depth and adding a new Health and Wellness ... and Wellness category will feature products like the award-winning ...
... Corporation (NASDAQ: ANGN ) today reported financial results ... Angeion reported revenues of $6.8 million compared to ... incurred a net loss of $81,000, or $(0.02) per diluted ... share in the comparable quarter last year. Financial results for ...
Cached Medicine Technology:Lifetime Products Enters New Product Category: Health and Wellness 2Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 2Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 3Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 4Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 5Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 6Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 7
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... Host Investor Conference Call on Thursday, May 14, ... Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ... development and commercialization of medically important, novel pharmaceutical ... renal disease and cancer (the "Company"), today announced ...
... finds , , WEDNESDAY, May 13 (HealthDay News) -- ... symptoms of bronchiolitis -- a virus-triggered condition that causes ... may reduce the risk of hospitalization by more than ... babies back to normal feeding sooner than either treatment ...
... Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: ... therapeutics for disease indications with large markets, today announced ... 2009., Selected Highlights, ... fiscal 2009 and up to the date of this ...
... start of dementia , , WEDNESDAY, May 13 (HealthDay News) ... the risk for developing Alzheimer,s disease in older people. ... well as complex physiological testing, may not be practical for ... fairly easy, such as age and mental status exams. We ...
... ROCHESTER, N.Y., May 13 A multi-million dollar ... to launch the University of Rochester ... recognized, comprehensive center for investigating and treating neurological ... dystrophy, stroke, and trauma to the brain and ...
... ANGELES, May 13 Runners, cyclists, fans and anyone interested ... the Memorial Day weekend leading up to the 24th Los ... Memorial Day, May 25. Coming up:>> Saturday, May 23: Run/Ex/09 ... Run/Ex/09, will open in the South Hall of the Los ...
Cached Medicine News:Health News:Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results 2Health News:Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results 3Health News:Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results 4Health News:Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results 5Health News:Combo Treatment Eases Wheezing in Babies 2Health News:Combo Treatment Eases Wheezing in Babies 3Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 2Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 3Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 4Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 5Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 6Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 7Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 8Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 9Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 10Health News:15-Point Test Gauges Alzheimer's Risk 2Health News:$10 Million Gift to Transform Neuromedicine at URMC 2Health News:$10 Million Gift to Transform Neuromedicine at URMC 3Health News:$10 Million Gift to Transform Neuromedicine at URMC 4Health News:$10 Million Gift to Transform Neuromedicine at URMC 5Health News:Full Calendar of Activities for 24th Los Angeles Marathon This Memorial Day Weekend 2
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
Each slide contains Giardia lamblia trophozoites applied as a mono-layer to the side....
... wells: a positive control containing ... in simulated sputum and a ... subsp. albus ATCC ® 3004 ... Control Slides should be stained ...
... With 384 Well Plate Capability The ... the original Equalizerexpandable and equal tip spacing, choice ... calibration capabilities. In addition, this model allows you ... for loading and accessing many gels and for ...
Medicine Products: